Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Depot Naltrexone for Opioid Addiction Relapse Prevention
NCT00781898Phase 3Completed
- Sponsor
- University of Pennsylvania
- Start
- Jun 2008
- Primary completion
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of naltrexone in opioid use disorder (OUD) (2 arms), sponsored by University of Pennsylvania. Primary endpoint: Relapse to Opioid Addiction at 6 months. Started Jun 2008; status: completed.
02
Drugs
naltrexone
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT00781898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00781898.